Navigation Links
MEDomics Announces a Growth Capital Investment from SpaGus Ventures LLC and Gary Augusta Joins MEDomics as Chief Operating Officer
Date:4/7/2011

AZUSA, Calif., April 7, 2011 /PRNewswire/ -- MEDomics, LLC provides NextGen sequence-based DNA diagnostic testing to enable personalized medicine in the genomics era and is transforming diagnostic testing for mitochondrial diseases.  MEDomics is proud to announce a growth capital investment from our partner, SpaGus Ventures LLC.  This second capital infusion from SpaGus will be used by MEDomics to fuel the continued growth of the company's industry leading tests for mitochondrial disease diagnosis (MitoDx and MitoNucleomeDx), that have produced over $2M in sales over a few months of limited release in the market.  In addition, Gary Augusta will become COO, join the MEDomics Board and lead the Corporate Development initiatives as the company adds senior leadership.

"We are pleased to continue and advance our relationship with SpaGus Ventures and Gary. The MitoDx and MitoNucleomeDX tests have got great traction in our target market and having Gary on board as an experienced partner further augments our senior business leadership," states Dr. Steve Sommer, Founder and President of MEDomics.

Gary Augusta states, "I am both honored and excited to invest in and work with the MEDomics team. What Dr. Sommer and the MEDomics team have accomplished is incredible and I look forward to contributing to the growth of this company and helping the patient community."

Mr. Augusta has over 20 years of experience as a CEO, CFO, growth capital investments, M&A and corporate development, angel and venture/micro private equity investing, strategy and operations management for small to Fortune 500 companies. SpaGus Ventures LLC is a fund focused on equity and debt investing for "unique" biomedical and technology companies with $1M-$10M of revenues who need capital for growth; typically for companies to "reach the next gate" of product or commercialization.  

MEDomics, LLC (www.medomics.com) is a molecular diagnostic laboratory that was founded in 2008 by Steve S. Sommer, MD, PhD, with the mission of providing Mutation Expert-based Diagnosis ("MED") to support the physician in delivering personalized medicine based on analysis of the patient's genome ("omics"). MEDomics was the first CLIA Certified Laboratory specializing in the clinical diagnostic application of Next Generation sequencing. The mutation experts at MEDomics provide quality interpretation to aid the practicing physician.  The staff at MEDomics "live and breathe" mitochondrial medicine.

Contact Information:
Jessica Thompson, Spaulding Thompson & Associates for MEDomics, LLC
949-233-8575, jessica@spauldingthompson.com

426 N. San Gabriel Ave.
Azusa, CA 91702
www.medomics.com
Phone: (626) 804-3645


'/>"/>
SOURCE MEDomics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions
2. Mtech Announces Finalists for University of Maryland $75K Business Plan Competition
3. Caliper Life Sciences Announces Date and Location of its 2011 Annual Meeting of Stockholders
4. Kimberly-Clark Health Care Announces Strategic Green Partnerships, Commitment to Reducing Medical Waste
5. Dendreon Announces Presentation of Data at the American Association of Cancer Research Annual Meeting
6. BioLife Solutions Announces Record Quarterly Revenue
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2011 Results
9. Medicomp, Inc. Announces Company Purchase From United Therapeutics
10. CareFusion Announces Departure of Chief Operating Officer
11. Danaher Announces Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... BOSTON , April 19, 2017  New research provides ... with advanced Parkinson,s, according to a study released today that ... 69th Annual Meeting in Boston , ... comes to the treatment of Parkinson,s disease, the oral drug ... of life and longevity. But as the disease progresses, the ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 /PRNewswire/ ... ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron Ehlen ... the signing of a three-year exclusive sales representation ... a dedicated sales team to introduce Imprimis, ophthalmic ... focused in 13 states in the U.S. Midwest. Precision ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... ... the much anticipated Regional Primary Care Spring Symposium on April 1, 2017 in ... medical community, offering physicians and healthcare providers an opportunity to learn about cutting ...
(Date:4/21/2017)... ... 2017 , ... Providing for loved ones before one’s passing is of paramount ... even begin. “Now more than ever there are some questions that are far too ... family,” said attorney Lisa Edgar Dickman, founder of the Law Offices of Lisa Edgar ...
(Date:4/21/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, wrote an ... crisis with solution to peace plan. Yisrayl says war has never brought peace and he ... the Creator Himself. , Yisrayl says war drums are beating all over the media ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal ... five common elements between the Obamacare program that most Republicans love to hate ... Warfarin poison to kill hogs. , Like Obamacare, the Miller program centers ...
(Date:4/21/2017)... ... ... National pest management association survey conducted in 2010 and more recently in 2015 ... period. In 2015 10% or US$750 million per annum of the total revenue from ... health and economic consequences of bed bug infestations are only just starting ...
Breaking Medicine News(10 mins):